Manglovo Health
Website unreachable since Oct 21, 2026
The startup is developing a once-weekly, non-steroidal contraceptive pill that offers a highly effective and safe alternative to traditional contraceptive methods. This solution addresses the need for more convenient and accessible contraceptive options on a global scale.
- Biotechnology
Funding
Founders
Product
Problem
Current daily oral contraceptives can be difficult to adhere to, leading to inconsistent hormone levels and potential unintended pregnancies. Existing long-acting methods like IUDs or implants require clinic visits and can have side effects that deter some users. This leaves a gap in the market for convenient, non-invasive, and easily discontinued contraceptive options.
Solution
This startup is developing a once-weekly oral contraceptive pill designed to provide consistent hormone levels and simplify adherence compared to daily regimens. The non-steroidal formulation aims to minimize hormonal side effects, offering a potentially safer alternative to traditional estrogen- or progestin-based pills. By extending the dosing interval to once a week, the pill seeks to improve convenience and reduce the risk of missed doses, while maintaining contraceptive efficacy. The easily-discontinued oral format provides users with greater control over their reproductive health.
Target Audience
The primary target audience is women of reproductive age seeking a convenient, non-invasive, and easily-discontinued contraceptive method with minimal hormonal side effects.
Features
- Non-steroidal formulation to minimize hormonal side effects
- Extended-release technology for consistent hormone levels over seven days
- Oral administration for ease of use and discontinuation
- Proprietary polymer coating to control drug release and absorption